Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Docetaxel in Advanced NSCLC
NCT00201825Phase 2Completed
- Start
- Dec 2004
- Primary completion
- Dec 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, docetaxel in non-small cell lung cancer (NSCLC). Started Dec 2004; status: completed.
02
Drugs
capecitabinedocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00201825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00201825.